Transcatheter hepatic arterial chemoembolization combined with Kangai injection for hepatitis B virus-related hepatocellular carcinoma: A protocol for a PRISMA-compliant meta-analysis.
Transcatheter hepatic arterial chemoembolization combined with Kangai injection for hepatitis B virus-related hepatocellular carcinoma: A protocol for a PRISMA-compliant meta-analysis.
复制标题
DOI：
10.1097/md.0000000000022565
复制
发表时间：
2020-10-09
期刊：
影响因子：
1.6
通讯作者：
Wang, Jing
中科院分区：
文献类型：
--
作者：
Wang, Wanpeng;Wang, Shurong;Liu, Jia;Liu, Yan;Mu, Ying;Wang, Jing
关键词：
抗癌注射液是一种著名的昆虫源性中药制剂，作为一种有前途的抗B病毒（HBV）相关性肝细胞癌（HCC）药物已被广泛应用。然而，其确切的临床疗效和安全性仍没有得到很好的研究。本研究旨在通过Meta分析总结康艾注射液治疗HBV相关HCC患者的有效性和安全性。从Google Scholar、PubMed、Excerpt Medica Database（Embase）、科克伦图书馆、Medline、Web of Science（WOS）、中国知网（CNKI）、中国科学期刊数据库（CSJ）中文版、生物医学文献数据库（CBM）和万方数据库。2000年1月至2020年9月发表的中文或英文论文将不受任何限制。研究选择和数据提取将由2名研究者独立进行。对总有效率（ORR）、疾病控制率（DCR）、生活质量（QoL）、临床症状、病毒学指标、免疫功能和不良事件等临床结局进行系统评价。使用Review Manager 5.3和Stata 14.0进行数据分析，并对文献质量进行评价。本研究的结果将发表在同行评议的期刊上，并为临床医生制定HBV相关HCC患者的最佳术后辅助治疗策略提供了有益的证据。我们的研究将客观地得出康艾注射液对乙型肝炎相关肝癌患者的疗效（ORR和DCR）、临床症状、病毒学指标、生活质量和免疫功能的影响。INPLASY202090014。
Kangai injection, a well-known insect-derived traditional Chinese medicine preparation, has been widely applied as a promising adjunctive drug for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, its exact clinical efficacy and safety is still not well investigated. In this study, we aimed to summarize the efficacy and safety of Kangai injection for patients with HBV-related HCC through the meta-analysis. All available randomized controlled trials (RCTs) and high-quality prospective cohort studies that investigated the efficacy and safety of Kangai injection for patients with HBV-related HCC were searched from ten electronic databases including Google Scholar, PubMed, Excerpt Medica Database (Embase), Cochrane Library, Medline, Web of Science (WOS), China National Knowledge Infrastructure (CNKI), China Scientific Journal Database (CSJ) Chinese, Biomedical Literature Database (CBM) and Wanfang Database. Papers in Chinese or English published from January 2000 to September 2020 will be included without any restrictions. Study selection and data extraction will be performed independently by 2 researchers. The clinical outcomes including overall response rate (ORR), disease control rate (DCR), quality of life (QoL), clinical symptoms, virological indicators, immune function and adverse events, were systematically evaluated. Review Manager 5.3 and Stata 14.0 were used for data analysis, and the quality of the literatures was also evaluated. The results of this study will be published in a peer-reviewed journal, and provide a helpful evidence for clinicians to formulate the best postoperative adjuvant treatment strategy for HBV-related HCC patients. Our study will draw an objective conclusion of the efficacy of Kangai injection on curative effect (ORR and DCR), clinical symptoms, virological indicators, QoL, and immune function in patients with HBV-related HCC. INPLASY202090014.